In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease

Thomas Lund; Michael Tveden Gundesen; Annette Juul Vangsted; Carsten Helleberg; Einar Haukås; Trine Silkjær; Jon Thor Asmussen; Elena Manuela Teodorescu; Bo Amdi Jensen; Tobias Schmidt Slørdahl; Hareth Nahi; Anders Waage; Niels Abildgaard; Fredrik Schjesvold; Nordic Myeloma Study Group

doi:10.1038/s41408-024-01046-2

In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease

Thomas Lund^*
, Michael Tveden Gundesen
, Annette Juul Vangsted
, Carsten Helleberg
, Einar Haukås
, Trine Silkjær
, Jon Thor Asmussen
, Elena Manuela Teodorescu
, Bo Amdi Jensen
, Tobias Schmidt Slørdahl
, Hareth Nahi
, Anders Waage
, Niels Abildgaard
, Fredrik Schjesvold
, Nordic Myeloma Study Group

^*Corresponding author for this work

Haematology

Research output: Contribution to journal › Letter › Research › peer-review

Original language	English
Article number	65
Number of pages	5
Journal	Blood cancer journal
Volume	14
Issue number	1
DOIs	https://doi.org/10.1038/s41408-024-01046-2
Publication status	Published - 15 Apr 2024

Access to Document

10.1038/s41408-024-01046-2

Cite this

Lund, T., Gundesen, M. T., Juul Vangsted, A., Helleberg, C., Haukås, E., Silkjær, T., Asmussen, J. T., Manuela Teodorescu, E., Amdi Jensen, B., Schmidt Slørdahl, T., Nahi, H., Waage, A., Abildgaard, N., Schjesvold, F., & Nordic Myeloma Study Group (2024). In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease. Blood cancer journal, 14(1), Article 65. https://doi.org/10.1038/s41408-024-01046-2

@article{8f39ee5260904295ad87d5e4e3d629b4,

title = "In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease",

author = "Thomas Lund and Gundesen, \{Michael Tveden\} and \{Juul Vangsted\}, Annette and Carsten Helleberg and Einar Hauk{\aa}s and Trine Silkj{\ae}r and Asmussen, \{Jon Thor\} and \{Manuela Teodorescu\}, Elena and \{Amdi Jensen\}, Bo and \{Schmidt Sl{\o}rdahl\}, Tobias and Hareth Nahi and Anders Waage and Niels Abildgaard and Fredrik Schjesvold and \{Nordic Myeloma Study Group\}",

year = "2024",

month = apr,

day = "15",

doi = "10.1038/s41408-024-01046-2",

language = "English",

volume = "14",

journal = "Blood cancer journal",

issn = "2044-5385",

publisher = "Springer Nature",

number = "1",

}

Lund, T, Gundesen, MT, Juul Vangsted, A, Helleberg, C, Haukås, E, Silkjær, T, Asmussen, JT, Manuela Teodorescu, E, Amdi Jensen, B, Schmidt Slørdahl, T, Nahi, H, Waage, A, Abildgaard, N, Schjesvold, F & Nordic Myeloma Study Group 2024, 'In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease', Blood cancer journal, vol. 14, no. 1, 65. https://doi.org/10.1038/s41408-024-01046-2

TY - JOUR

T1 - In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease

AU - Lund, Thomas

AU - Gundesen, Michael Tveden

AU - Juul Vangsted, Annette

AU - Helleberg, Carsten

AU - Haukås, Einar

AU - Silkjær, Trine

AU - Asmussen, Jon Thor

AU - Manuela Teodorescu, Elena

AU - Amdi Jensen, Bo

AU - Schmidt Slørdahl, Tobias

AU - Nahi, Hareth

AU - Waage, Anders

AU - Abildgaard, Niels

AU - Schjesvold, Fredrik

AU - Nordic Myeloma Study Group

PY - 2024/4/15

Y1 - 2024/4/15

U2 - 10.1038/s41408-024-01046-2

DO - 10.1038/s41408-024-01046-2

M3 - Letter

C2 - 38622134

SN - 2044-5385

VL - 14

JO - Blood cancer journal

JF - Blood cancer journal

IS - 1

M1 - 65

ER -